Cancer Immunotherapy Drug Discovery Outsourcing Market Analysis Report By Drug, By Service, By Cancer Type (Lung, Breast, Colorectal, Melanoma, Prostate, Pancreatic), And Segment Forecasts, 2018 - 2025

Published: Nov, 2018 | Pages: 95 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)

The global cancer immunotherapy drug discovery outsourcing market size is projected to reach USD 1.7Billion by 2025, according to a new report by Grand View Research, Inc., rising at a CAGR of 13.5% during the forecast period. Increasing prevalence of cancer and rising mortality associated with cancer, along with growing development in the field of cancer immunotherapy, are anticipated to stimulate the growth of the market.

In order to maintain pace with increasing competition in the cancer therapeutics industry, pharmaceutical companies spend 2.5% more than other high tech industries in the in-house R&D. Hence, they are swiftly shifting towards outsourcing of drug discovery in order to achieve lower in-house R&D costs.

Additionally, favorable tax credit allows pharmaceutical companies to appropriately plan their global projects with a reputed CRO and therefore, receive benefits and reduce problems associated with taxation authorities or other bodies administering such incentive programs.

Several new molecules for cancer immunotherapy and new immunotherapeutic options, such as tumor infiltrating lymphocytes, check point inhibitors immunomodulators, and CAR-T cell therapy, have been introduced. Some are in the pipeline and are being tested for their ability to provide better cancer treatment

Further key findings from the report suggest:

• Monoclonal antibodies emerged as the largest segment in 2017 because of increasing regulatory approvals and higher efficacy

• Target identification and validation accounted for the largest share in the global market owing to higher costs incurred and increased investments in new drug development

• North America dominated the market with the largest share in 2017. Rising incidence of cancer and increasing demand for novel technologies are facilitating the dominance of the region during the forecast period

• Some of the key players are Covance, Inc.; Explicyte; Aquila BioMedical; Horizon Discovery Group PLC; Crown Bioscience, Inc.; Promega Corporation; HD Biosciences Co., Ltd.; BPS Bioscience, Inc.; Genscript Biotech Corporation; DiscoverX Corporation; Celentyx Ltd.; ImmunXperts SA; Personalis, Inc.; STC Biologics; and Molecular Imaging, Inc. dominated the cancer immunotherapy drug discovery outsourcing market.

 Table of Contents

Chapter 1 Methodology and Scope
                 1.1 Research Methodology
                 1.2 Research Scope and Assumptions
Chapter 2 Executive Summary
                 2.1 Market Summary
Chapter 3 Market Variables, Trends & Scope
                 3.1 Market Segmentation
Chapter 4 Industry Outlook
                 4.1 Market Variable Analysis
                     4.1.1 Increasing in-house R & D costs
                     4.1.2 Increasing adoption of advanced technologies
                     4.1.3 Mergers and acquisitions
                     4.1.4 Tax credit
                 4.2 Market Restraint Analysis
                     4.2.1 Quality issues involved with drug discovery cro services
                     4.2.2 Intellectual property right issues
                 4.3 Porter's Five Forces Analysis
Chapter 5 Drug Type Business Analysis
                 5.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: Drug Movement Analysis
                 5.2 Monoclonal Antibodies
                     5.2.1 Monoclonal antibodies market estimates and forecast, 2014 - 2025
                 5.3 Immunomodulators
                     5.3.1 Immunomodulators market estimates and forecast, 2014 - 2025
                 5.4 Cancer Vaccines and Oncolytic Therapies
                     5.4.1 Cancer vaccines and oncolytic therapies market estimates and forecast, 2014 - 2025
                 5.5 Others
                     5.5.1 Others market estimates and forecast, 2014 - 2025
Chapter 6 Service Business Analysis
                 6.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: service Movement Analysis
                 6.2 Target Identification and Validation
                     6.2.1 Target identification and validation market estimates and forecast, 2014 - 2025
                 6.3 Lead screening and Characterization
                     6.3.1 Lead screening and characterization market estimates and forecast, 2014 - 2025
                 6.4 Cell based Assays
                     6.4.1 Cell based assays market estimates and forecast, 2014 - 2025
Chapter 7 Cancer Business Analysis
                 7.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: Cancer Movement Analysis
                 7.2 Lung Cancer
                     7.2.1 Lung cancer market estimates and forecast, 2014 - 2025
                 7.3 Breast Cancer
                     7.3.1 Breast cancer market estimates and forecast, 2014 - 2025
                 7.4 Colorectal Cancer
                     7.4.1 Colorectal cancer market estimates and forecast, 2014 - 2025
                 7.5 Melanoma
                     7.5.1 Melanoma market estimates and forecast, 2014 - 2025
                 7.6 Prostate Cancer
                     7.6.1 Prostate cancer market estimates and forecast, 2014 - 2025
                 7.7 Head and Neck Cancer
                     7.7.1 Head and neck cancer market estimates and forecast, 2014 - 2025
                 7.8 Ovarian Cancer
                     7.8.1 Ovarian cancer market estimates and forecast, 2014 - 2025
                 7.9 Pancreatic Cancer
                     7.9.1 Pancreatic cancer market estimates and forecast, 2014 - 2025
Chapter 8 Regional Business Analysis
                 8.1 Cancer Immunotherapy Drug Discovery Outsourcing Market: Regional Movement Analysis
                 8.2 North America
                     8.2.1 North America market estimates and forecast, 2014 - 2025
                     8.2.2 U.S.
                         8.2.2.1 U.S. market estimates and forecast, 2014 - 2025
                     8.2.3 Canada
                         8.2.3.1 Canada market estimates and forecast, 2014 - 2025
                 8.3 Europe
                     8.3.1 Europe market estimates and forecast, 2014 - 2025
                     8.3.2 Germany
                         8.3.2.1 Germany market estimates and forecast, 2014 - 2025
                     8.3.3 UK
                         8.3.3.1 UK market estimates and forecast, 2014 - 2025
                 8.4 Asia Pacific
                     8.4.1 Asia Pacific market estimates and forecast, 2014 - 2025
                     8.4.2 India
                         8.4.2.1 India market estimates and forecast, 2014 - 2025
                     8.4.3 China
                         8.4.3.1 China market estimates and forecast, 2014 - 2025
                 8.5 Latin America
                     8.5.1 Latin america market estimates and forecast, 2014 - 2025
                     8.5.2 Brazil
                         8.5.2.1 Brazil market estimates and forecast, 2014 - 2025
                     8.5.3 Mexico
                         8.5.3.1 Mexico market estimates and forecast, 2014 - 2025
                 8.6 Middle East & Africa
                     8.6.1 Middle east and africa market estimates and forecast, 2014 - 2025
                     8.6.2 South Africa
                         8.6.2.1 South Africa market estimates and forecast, 2014 - 2025
Chapter 9 Company Profile
                 9.1 Strategy Framework
                 9.2 Explicit Immuno-Oncology
                     9.2.1 Company overview
                     9.2.2 SWOT analysis
                     9.2.3 Product benchmarking
                     9.2.4 Strategic initiatives
                 9.3 Aquila Biomedical
                     9.3.1 Company overview
                     9.3.2 SWOT analysis
                     9.3.3 Product benchmarking
                     9.3.4 Strategic initiatives
                 9.4 Horizon Discovery Group plc
                     9.4.1 Company overview
                     9.4.2 Financial performance
                     9.4.3 Product benchmarking
                     9.4.4 Strategic initiatives
                     9.4.5 SWOT analysis
                 9.5 Crown Bioscience Inc.
                     9.5.1 Company overview
                     9.5.2 SWOT analysis
                     9.5.3 Product benchmarking
                     9.5.4 Strategic initiatives
                 9.6 Promega Corporation
                     9.6.1 Company overview
                     9.6.2 SWOT analysis
                     9.6.3 Product benchmarking
                     9.6.4 Strategic initiatives
                 9.7 HD Biosciences Co. Ltd.
                     9.7.1 Company overview
                     9.7.2 SWOT analysis
                     9.7.3 Product benchmarking
                     9.7.4 Strategic initiatives
                 9.8 BPS Biosciences Inc.
                     9.8.1 Company overview
                     9.8.2 SWOT analysis
                     9.8.3 Product benchmarking
                     9.8.4 Strategic initiatives
                 9.9 Gen script Biotech Corporation
                     9.9.1 Company overview
                     9.9.2 Financial performance
                     9.9.3 Product benchmarking
                     9.9.4 Strategic initiatives
                     9.9.5 SWOT analysis
                 9.10 Celentyx Ltd.
                     9.10.1 Company overview
                     9.10.2 SWOT analysis
                     9.10.3 Product benchmarking
                     9.10.4 Strategic initiatives
                 9.11 ImmuneXperts SA
                     9.11.1 Company overview
                     9.11.2 SWOT analysis
                     9.11.3 Product benchmarking
                     9.11.4 Strategic initiatives
                 9.12 Personalis
                     9.12.1 Company overview
                     9.12.2 Product benchmarking
                     9.12.3 Strategic initiatives
                     9.12.4 SWOT analysis
                 9.13 STC Biologics
                     9.13.1 Company overview
                     9.13.2 SWOT analysis
                     9.13.3 Product benchmarking
                     9.13.4 Strategic initiatives
                 9.14 Molecular Imaging Inc. (MI Bioresearch Inc.)
                     9.14.1 Company overview
                     9.14.2 SWOT analysis
                     9.14.3 Product benchmarking
                     9.14.4 Strategic initiatives
                 9.15 Covance, Inc.
                     9.15.1 Company overview
                     9.15.2 Financial performance
                     9.15.3 Product benchmarking
                     9.15.4 Strategic initiatives
                     9.15.5 Swot analysis

List of Tables

TABLE 1 List of Strategic Partnerships
TABLE 2 Gap analysis: Cancer immunotherapy drug discovery outsourcing services
TABLE 3 North America cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
TABLE 4 North America cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
TABLE 5 North America cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
TABLE 6 U.S. cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
TABLE 7 U.S. cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
TABLE 8 U.S. cancer immunotherapy drug discovery outsourcing market outsourcing market, by cancer type, 2014 - 2025 (USD Million)
TABLE 9 Canada cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
TABLE 10 Canada cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
TABLE 11 Canada cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
TABLE 12 Europe cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
TABLE 13 Europe cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
TABLE 14 Europe cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
TABLE 15 U.K. cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
TABLE 16 U.K. cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
TABLE 17 U.K. cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
TABLE 18 Germany cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
TABLE 19 Germany cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
TABLE 20 Germany cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
TABLE 21 Asia Pacific cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
TABLE 22 Asia Pacific cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
TABLE 23 Asia Pacific cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
TABLE 24 China cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
TABLE 25 China cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
TABLE 26 China cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
TABLE 27 India cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
TABLE 28 India cancer immunotherapy drug discovery outsourcing market, by service Type, 2014 - 2025 (USD Million)
TABLE 29 India cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
TABLE 30 Latin America cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
TABLE 31 Latin America cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
TABLE 32 Latin America cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
TABLE 33 Brazil cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
TABLE 34 Brazil cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
TABLE 35 Brazil cancer immunotherapy drug discovery outsourcing market, by cancer type , 2014 - 2025 (USD Million)
TABLE 36 Mexico cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
TABLE 37 Mexico cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
TABLE 38 Mexico cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
TABLE 39 MEA cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
TABLE 40 MEA cancer immunotherapy drug discovery outsourcing market, by service Type, 2014 - 2025 (USD Million)
TABLE 41 MEA cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)
TABLE 42 South Africa cancer immunotherapy drug discovery outsourcing market, by drug type, 2014 - 2025 (USD Million)
TABLE 43 South Africa cancer immunotherapy drug discovery outsourcing market, by service type, 2014 - 2025 (USD Million)
TABLE 44 South Africa cancer immunotherapy drug discovery outsourcing market, by cancer type, 2014 - 2025 (USD Million)

List of Figures

FIG. 1 Cancer immunotherapy drug discovery outsourcing market snapshot
FIG. 2 Cancer immunotherapy drug discovery outsourcing market segmentation
FIG. 3 Cancer immunotherapy drug discovery outsourcing market driver impact
FIG. 4 Cancer immunotherapy drug discovery outsourcing market restraint impact
FIG. 5 SWOT analysis, By Factor (political & legal economic and technological)
FIG. 6 Porter's five forces analysis
FIG. 7 Cancer immunotherapy drug discovery outsourcing market: Drug type outlook and key takeaways
FIG. 8 Cancer immunotherapy drug discovery outsourcing market: Drug movement analysis
FIG. 9 Monoclonal antibodies market estimates and forecast, 2014 - 2025
FIG. 10 Immunomodulators market estimates and forecast, 2014 - 2025
FIG. 11 Cancer vaccines and oncolytic therapies market estimates and forecast, 2014 - 2025
FIG. 12 Others market estimates and forecast, 2014 - 2025
FIG. 13 Cancer immunotherapy drug discovery outsourcing market: Service outlook and key takeaways
FIG. 14 Cancer immunotherapy drug discovery outsourcing market: Service movement analysis
FIG. 15 Target identification and validation market estimates and forecast, 2014 - 2025
FIG. 16 Lead screening and characterization market estimates and forecast, 2014 - 2025
FIG. 17 Cell based assays market estimates and forecast, 2014 - 2025
FIG. 18 Cancer immunotherapy drug discovery outsourcing market: Cancer outlook and key takeaways
FIG. 19 Cancer immunotherapy drug discovery outsourcing market: Service movement analysis
FIG. 20 Lung cancer market estimates and forecast, 2014 - 2025
FIG. 21 Breast cancer market estimates and forecast, 2014 - 2025
FIG. 22 Colorectal cancer market estimates and forecast, 2014 - 2025
FIG. 23 Melanoma market estimates and forecast, 2014 - 2025
FIG. 24 Prostate cancer market estimates and forecast, 2014 - 2025
FIG. 25 Head and neck cancer market estimates and forecast, 2014 - 2025
FIG. 26 Ovarian cancer market estimates and forecast, 2014 - 2025
FIG. 27 Pancreatic cancer market estimates and forecast, 2014 - 2025
FIG. 28 Cancer immunotherapy drug discovery outsourcing market: regional outlook and key takeaways
FIG. 29 Cancer immunotherapy drug discovery outsourcing market: Regional movement analysis
FIG. 30 North America
FIG. 31 North America market estimates and forecast, 2014 - 2025
FIG. 32 U.S. market estimates and forecast, 2014 - 2025
FIG. 33 Canada market estimates and forecast, 2014 - 2025
FIG. 34 Europe
FIG. 35 Europe market estimates and forecast, 2014 - 2025
FIG. 36 Germany market estimates and forecast, 2014 - 2025
FIG. 37 UK market estimates and forecast, 2014 - 2025
FIG. 38 Asia-Pacific
FIG. 39 Asia-Pacific market estimates and forecast, 2014 - 2025
FIG. 40 India market estimates and forecast, 2014 - 2025
FIG. 41 China market estimates and forecast, 2014 - 2025
FIG. 42 Latin America
FIG. 43 Latin America market estimates and forecast, 2014 - 2025
FIG. 44 Brazil market estimates and forecast, 2014 - 2025
FIG. 45 Mexico market estimates and forecast, 2014 - 2025
FIG. 46 Middle East & Africa
FIG. 47 Middle East and Africa market estimates and forecast, 2014 - 2025
FIG. 48 South Africa market estimates and forecast, 2014 - 2025
FIG. 49 Strategy Framework